Logo

Biogen Reports Results of Spinraza (nusinersen) in P-II NURTURE Study as a Foundation of Care in Spinal Muscular Atrophy

Share this

Biogen Reports Results of Spinraza (nusinersen) in P-II NURTURE Study as a Foundation of Care in Spinal Muscular Atrophy

Shots:

  • The P-II NURTURE study involves assessing of Spinraza in comparison to the natural history of the disease in 25 pre-symptomatic infants with SMA
  • The P-II NURTURE study resulted in achieving motor milestones including 100% of children sitting without support & 88% walking independently. The results support long-term safety & efficacy of Spinraza demonstrating continuous improvement in attaining motor milestones
  • Spinraza is a disease-modifying & an approved therapy for treating infants- children and adults with SMA- currently available in 40+ countries- being evaluated in a SHINE extension study of children with infantile and later-onset SMA as well the CS2/CS12 analysis of older patients

Click here to read full press release/ article

| Ref: Biogen | Image: Biogen


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions